Avivagen Inc.
VIVXF
$0.00
$0.000.00%
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 535.80K | 543.20K | 555.60K | 720.60K | 318.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 535.80K | 543.20K | 555.60K | 720.60K | 318.10K |
| Cost of Revenue | 306.80K | 315.00K | 324.00K | 413.40K | 170.00K |
| Gross Profit | 228.70K | 227.90K | 231.40K | 307.10K | 148.10K |
| SG&A Expenses | 2.44M | 3.26M | 3.73M | 4.08M | 4.13M |
| Depreciation & Amortization | 45.70K | 57.50K | 62.30K | 68.10K | 75.50K |
| Other Operating Expenses | -31.70K | -35.60K | -40.40K | -38.70K | -130.20K |
| Total Operating Expenses | 2.77M | 3.60M | 4.07M | 4.53M | 4.24M |
| Operating Income | -2.23M | -3.06M | -3.52M | -3.81M | -3.92M |
| Income Before Tax | -3.46M | -4.24M | -4.35M | -4.72M | -5.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.46 | -4.24 | -4.35 | -4.72 | -5.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.46M | -4.24M | -4.35M | -4.72M | -5.10M |
| EBIT | -2.23M | -3.06M | -3.52M | -3.81M | -3.92M |
| EBITDA | -2.21M | -3.03M | -3.48M | -3.75M | -3.86M |
| EPS Basic | -0.05 | -0.07 | -0.07 | -0.08 | -0.09 |
| Normalized Basic EPS | -0.03 | -0.04 | -0.05 | -0.05 | -0.05 |
| EPS Diluted | -0.05 | -0.07 | -0.07 | -0.08 | -0.09 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.05 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 277.50M | 262.99M | 244.98M | 224.75M | 236.62M |
| Average Diluted Shares Outstanding | 277.50M | 262.99M | 244.98M | 224.75M | 236.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |